Monitoring and Managing Cardiovascular Risk in Immune Mediated Inflammatory Diseases

被引:10
作者
Anyfanti, Panagiota [1 ]
Dara, Athanasia [2 ]
Angeloudi, Elena [1 ]
Bekiari, Eleni [1 ]
Dimitroulas, Theodoros [2 ]
Kitas, George D. [3 ,4 ]
机构
[1] Aristotle Univ Thessaloniki, Hippokrat Hosp, Med Dept 2, Thessaloniki, Greece
[2] Aristotle Univ Thessaloniki, Hippokrat Hosp, Dept Internal Med 4, Thessaloniki, Greece
[3] Russells Hall Hosp, Dept Rheumatol, Dudley Grp NHS Fdn Trust, Dudley, England
[4] Univ Birmingham, Sch Sport Exercise & Rehabil Sci, Birmingham, W Midlands, England
关键词
chronic inflammatory diseases; cardiovascular risk assessment; lifestyle modifications; pharmacological management; SYSTEMIC-LUPUS-ERYTHEMATOSUS; NONSTEROIDAL ANTIINFLAMMATORY DRUGS; RHEUMATOID-ARTHRITIS; SUBCLINICAL ATHEROSCLEROSIS; MYOCARDIAL-INFARCTION; PSORIATIC-ARTHRITIS; ANTIRHEUMATIC DRUGS; ALPHA THERAPY; METHOTREXATE; VALIDATION;
D O I
10.2147/JIR.S276986
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Cardiovascular disease (CVD) is common in immune-mediated inflammatory diseases (IMIDs) and it is predominately attributed to the interplay between chronic inflammation and traditional CVD risk factors. CVD has significant impact on the survival of patients with IMIDs as it is associated with increased morbidity and mortality. Despite recommendations for monitoring and managing CVD in patients with IMIDs, the individual CVD risk assessment remains problematic as CVD risk calculators for the general population consistently underestimate the risk in patients with IMIDs. Application of new technologies utilizing artificial intelligence techniques have shown promising potential for tailoring predictive medicine to the individual patient, but further validation of their role in clinical decision-making is warranted. In the meantime, individuals with IMIDs should be encouraged to adopt behavioral interventions targeting at modifiable lifestyle CVD risk factors, whereas rheumatologists need to be well aware of the unfavorable effects of antirheumatic medication on various CVD risk factors and outcomes. In the current paper, we aim to provide an overview of current and emerging strategies for mitigating CVD risk in patients with IMIDs, based on a practical approach.
引用
收藏
页码:6893 / 6906
页数:14
相关论文
共 128 条
  • [11] The Spectrum of Interstitial Lung Disease Associated with Autoimmune Diseases: Data of a 3.6-Year Prospective Study from a Referral Center of Interstitial Lung Disease and Lung Transplantation
    Atienza-Mateo, Belen
    Remuzgo-Martinez, Sara
    Mora Cuesta, Victor Manuel
    Iturbe-Fernandez, David
    Fernandez-Rozas, Sonia
    Prieto-Pena, Diana
    Calderon-Goercke, Monica
    Corrales, Alfonso
    Blanco Rodriguez, Gerardo
    Gomez-Roman, Jose Javier
    Gonzalez-Gay, Miguel Angel
    Cifrian, Jose Manuel
    [J]. JOURNAL OF CLINICAL MEDICINE, 2020, 9 (06)
  • [12] Risk of incident cardiovascular events in patients with rheumatoid arthritis: a meta-analysis of observational studies
    Avina-Zubieta, Juan Antonio
    Thomas, Jamie
    Sadatsafavi, Mohsen
    Lehman, Allen J.
    Lacaille, Diane
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 2012, 71 (09) : 1524 - 1529
  • [13] Bacon P. A., 2002, Autoimmunity Reviews, V1, P338, DOI 10.1016/S1568-9972(02)00100-3
  • [14] THE SIGNIFICANCE OF VASCULAR INFLAMMATION IN RHEUMATOID-ARTHRITIS
    BACON, PA
    KITAS, GD
    [J]. ANNALS OF THE RHEUMATIC DISEASES, 1994, 53 (10) : 621 - 623
  • [15] Systematic Review and Meta-Analysis: Anti-Tumor Necrosis Factor α Therapy and Cardiovascular Events in Rheumatoid Arthritis
    Barnabe, Cheryl
    Martin, Billie-Jean
    Ghali, William A.
    [J]. ARTHRITIS CARE & RESEARCH, 2011, 63 (04) : 522 - 529
  • [16] Mortality and Cardiovascular Burden of Systemic Lupus Erythematosus in a US Population-based Cohort
    Bartels, Christie M.
    Buhr, Kevin A.
    Goldberg, Jerry W.
    Bell, Carolyn L.
    Visekruna, Maja
    Nekkanti, Swapna
    Greenlee, Robert T.
    [J]. JOURNAL OF RHEUMATOLOGY, 2014, 41 (04) : 680 - 687
  • [17] Hydroxychloroquine Use and Decreased Risk of Diabetes in Rheumatoid Arthritis Patients
    Bili, Androniki
    Sartorius, Jennifer A.
    Kirchner, H. Lester
    Morris, Stephanie J.
    Ledwich, Lindsay J.
    Antohe, Jana L.
    Dancea, Sorina
    Newman, Eric D.
    Wasko, Mary Chester M.
    [J]. JCR-JOURNAL OF CLINICAL RHEUMATOLOGY, 2011, 17 (03) : 115 - 120
  • [18] Risk factors for coronary heart disease in women with systemic lupus erythematosus -: The Toronto Risk Factor Study
    Bruce, IN
    Urowitz, MB
    Gladman, DD
    Ibañez, D
    Steiner, G
    [J]. ARTHRITIS AND RHEUMATISM, 2003, 48 (11): : 3159 - 3167
  • [19] Methotrexate-how does it really work?
    Chan, Edwin S. L.
    Cronstein, Bruce N.
    [J]. NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (03) : 175 - 178
  • [20] Risk of type 2 diabetes an cardiovascular disease in an incident cohort of people with psoriatic arthritis: a population-based cohort study
    Charlton, Rachel
    Green, Amelia
    Shaddick, Gavin
    Snowball, Julia
    Nightingale, Alison
    Tillett, William
    Smith, Catherine
    McHugh, Neil
    Barton, Anne
    Bojke, Laura
    Brooke, Melanie
    Brown, Sarah
    Coates, Laura
    Davies, Claire
    Dures, Emma
    Fernandez, Catherine
    Fitzgerald, Oliver
    Harris, Helen
    Helliwell, Philip
    James, Jana
    Madhok, Vishnu
    Packham, Jon
    Parkinson, Andrew
    Spackman, Eldon
    [J]. RHEUMATOLOGY, 2019, 58 (01) : 144 - 148